The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys ...

Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending ...

Investing.com -- Roche (SIX: ROG) shares fell 2% Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy, following two reported ...

Roche (OTCQX:RHHBY) announced that physicians should no longer prescribe Elevidys for non-ambulatory patients. In a statement on Sunday, the Swiss drugmaker added that enrollment and dosing of non ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...

Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss pharmaceutical company said Sunday that the dosing of non-ambulatory patients ...